• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Bridging the Gap between Trial Adverse Events and Real-World Data.弥合试验不良事件与真实世界数据之间的差距。
Cancer Res Treat. 2024 Jul;56(3):972-973. doi: 10.4143/crt.2024.019. Epub 2024 Jan 10.
2
Reporting and analysis of immunotherapy trials adverse events: what is going wrong, how to do better?免疫治疗试验不良事件的报告与分析：哪里出了问题，如何做得更好？
Ann Oncol. 2024 Jun;35(6):569-570. doi: 10.1016/j.annonc.2024.03.006. Epub 2024 Mar 26.
3
A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.一种标准化方法，用于比较银屑病临床试验和真实世界人群中治疗安全性和疗效结局。
Br J Dermatol. 2019 Dec;181(6):1265-1271. doi: 10.1111/bjd.17849. Epub 2019 Jul 2.
4
Rare adverse events in clinical trials: understanding the rule of three.临床试验中的罕见不良事件：理解“三法则”
BMJ Evid Based Med. 2018 Feb;23(1):6. doi: 10.1136/ebmed-2017-110885.
5
Under-reporting of harm in clinical trials.临床试验中的伤害漏报。
Lancet Oncol. 2016 May;17(5):e209-19. doi: 10.1016/S1470-2045(16)00152-2. Epub 2016 Apr 27.
6
Hidden Side Effects.潜在副作用
Sci Am. 2016 Dec 20;316(1):18. doi: 10.1038/scientificamerican0117-18b.
7
Statistical methods for the analysis of adverse event data.不良事件数据分析的统计方法。
Pharm Stat. 2016 Jul;15(4):290-1. doi: 10.1002/pst.1759. Epub 2016 Jun 20.
8
Apixaban for Treating Venous Thromboembolism in Real-World Clinical Practice.阿哌沙班用于真实世界临床实践中治疗静脉血栓栓塞症
Thromb Haemost. 2018 Nov;118(11):1850-1851. doi: 10.1055/s-0038-1675241. Epub 2018 Oct 17.
9
How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine.如何调查在COVID-19疫苗临床试验期间报告的严重不良事件。
Drug Saf. 2021 Jan;44(1):1-5. doi: 10.1007/s40264-020-01018-y. Epub 2020 Nov 21.
10
Exploring the Landscape of Immune Checkpoint Inhibitor-Induced Adverse Events Through Big Data Mining of Pan-Cancer Clinical Trials.通过泛癌临床试验的大数据挖掘探索免疫检查点抑制剂诱导的不良事件情况
Oncologist. 2024 May 3;29(5):415-421. doi: 10.1093/oncolo/oyae012.

本文引用的文献

1
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.布加替尼对比阿来替尼用于克唑替尼治疗后进展的 ALK 阳性 NSCLC ：III 期 ALTA-3 试验结果。
J Thorac Oncol. 2023 Dec;18(12):1743-1755. doi: 10.1016/j.jtho.2023.08.010. Epub 2023 Aug 12.
2
First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: Real-World Data.一线阿来替尼对比布加替尼治疗伴有 ALK 重排的晚期非小细胞肺癌：真实世界数据。
Cancer Res Treat. 2024 Jan;56(1):61-69. doi: 10.4143/crt.2023.461. Epub 2023 Jul 14.
3
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.布加替尼与克唑替尼用于初治的晚期ALK阳性非小细胞肺癌：3期ALTA-1L试验的最终结果
J Thorac Oncol. 2021 Dec;16(12):2091-2108. doi: 10.1016/j.jtho.2021.07.035. Epub 2021 Sep 16.
4
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.在 ALEX 研究中，未经治疗的晚期 ALK 阳性非小细胞肺癌患者的更新总生存和最终无进展生存数据。
Ann Oncol. 2020 Aug;31(8):1056-1064. doi: 10.1016/j.annonc.2020.04.478. Epub 2020 May 11.

Bridging the Gap between Trial Adverse Events and Real-World Data.

作者信息

Kim Sang Hyuk, Lee Hyun, Park Dong Won

机构信息

Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Dongguk University Gyeongju Hospital, Dongguk University College of Medicine, Gyeongju, Korea.

Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea.

出版信息

Cancer Res Treat. 2024 Jul;56(3):972-973. doi: 10.4143/crt.2024.019. Epub 2024 Jan 10.

DOI:10.4143/crt.2024.019
PMID:38228084
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11261195/
Abstract
摘要